Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Raw Materials (2022 - 2025)

Arcutis Biotherapeutics has reported Raw Materials over the past 4 years, most recently at $5.0 million for Q4 2025.

  • Quarterly results put Raw Materials at $5.0 million for Q4 2025, up 17.37% from a year ago — trailing twelve months through Dec 2025 was $5.0 million (up 17.37% YoY), and the annual figure for FY2025 was $5.0 million, up 17.37%.
  • Raw Materials for Q4 2025 was $5.0 million at Arcutis Biotherapeutics, down from $6.1 million in the prior quarter.
  • Over the last five years, Raw Materials for ARQT hit a ceiling of $11.2 million in Q3 2023 and a floor of $3.5 million in Q3 2022.
  • Median Raw Materials over the past 4 years was $6.3 million (2023), compared with a mean of $6.6 million.
  • Biggest five-year swings in Raw Materials: soared 220.64% in 2023 and later tumbled 63.49% in 2024.
  • Arcutis Biotherapeutics' Raw Materials stood at $5.7 million in 2022, then soared by 75.84% to $10.0 million in 2023, then crashed by 56.79% to $4.3 million in 2024, then increased by 17.37% to $5.0 million in 2025.
  • The last three reported values for Raw Materials were $5.0 million (Q4 2025), $6.1 million (Q3 2025), and $6.7 million (Q2 2025) per Business Quant data.